Company Overview - Phreesia (PHR) shares increased by 5.6% to $30.01 in the last trading session, with a higher-than-average trading volume, compared to a 4.9% gain over the past four weeks [1] - The company is recognized for its leadership, as Sally Thayer, Vice President of Product Management, was named to The Software Report's list of the Top 50 Women Leaders in Software of 2024, marking the seventh consecutive year a female leader from Phreesia has received this honor [2] Financial Performance - Phreesia is expected to report a quarterly loss of $0.19 per share, reflecting a year-over-year improvement of 66.1%, with anticipated revenues of $108.91 million, up 14.6% from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Phreesia operates within the Zacks Medical Info Systems industry, which includes other companies like Pulmonx Corporation (LUNG), whose shares also saw a 5.3% increase to $7.38 in the last trading session, with a 4.3% return over the past month [4] - Pulmonx's consensus EPS estimate for its upcoming report has remained unchanged at -$0.43, representing a year-over-year change of -19.4% [5]

Core Viewpoint - Phreesia's stock has shown significant performance, increasing by 16.4% over the past month and reaching a 52-week high of $29.36, outperforming the broader medical sector and medical information systems industry [1][2]. Financial Performance - Phreesia has consistently exceeded earnings expectations, reporting an EPS of -$0.25 against a consensus estimate of -$0.29 in its last earnings report [2]. - For the current fiscal year, Phreesia is projected to have an EPS of -$1.10 with revenues of $419.04 million, reflecting a 56.18% change in EPS and a 17.61% change in revenues [3]. - The next fiscal year forecasts an EPS of -$0.38 and revenues of $476.77 million, indicating a year-over-year change of 66.18% in EPS and 13.78% in revenues [3]. Valuation Metrics - Despite reaching a 52-week high, the future valuation metrics of Phreesia need to be assessed to determine if the stock has become overvalued [4]. Zacks Style Scores - Phreesia has a Value Score of D, a Growth Score of A, and a Momentum Score of D, resulting in a combined VGM Score of B [6]. Zacks Rank - Phreesia holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates, suggesting potential for further stock price appreciation [7].

Core Viewpoint - Phreesia (PHR) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending January 2025, Phreesia is expected to earn -$1.10 per share, representing a 56.2% change from the previous year's reported figure, with a 10.2% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade of Phreesia to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Technical Analysis - Phreesia Inc (PHR) has reached a key technical support level with its 50-day simple moving average crossing above its 200-day simple moving average, forming a "golden cross" [1] - A golden cross is a bullish technical chart pattern indicating potential upward momentum, typically involving the 50-day and 200-day moving averages [2] - The golden cross pattern consists of three stages: a downtrend bottoming out, a crossover of moving averages triggering a positive trend reversal, and continued upward momentum [3] Recent Performance - PHR has gained 11.8% over the past four weeks [4] - The company currently holds a 3 (Hold) rating on the Zacks Rank, suggesting potential for a breakout [4] Earnings Outlook - PHR has a positive earnings outlook with no earnings estimate cuts for the current quarter and 5 upward revisions in the past 60 days [4] - The Zacks Consensus Estimate for PHR has increased [4] Investment Consideration - Investors may consider PHR for potential gains due to its technical indicators and positive earnings estimate revisions [5]

Core Viewpoint - Phreesia (PHR) has shown a significant price increase of 25.5% over the past four weeks, with a mean price target of $29.80 indicating a potential upside of 25% from the current price of $23.84 [1] Group 1: Price Target Insights - The consensus price target is often viewed with skepticism due to analysts' tendency to set overly optimistic targets, which may mislead investors [2][8] - A tight clustering of price targets, indicated by a low standard deviation of $3.30, suggests strong agreement among analysts regarding the stock's price movement [6] - The lowest price estimate is $23, indicating a potential decline of 3.5%, while the highest estimate suggests a 51% increase to $36 [6] Group 2: Earnings Estimates and Analyst Sentiment - The Zacks Consensus Estimate for the current year has increased by 8.6%, reflecting positive sentiment among analysts with no negative revisions [4] - Analysts' growing optimism regarding PHR's earnings prospects is supported by strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - PHR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [12]

Company Overview - Phreesia (NYSE: PHR) provides software solutions for healthcare providers, focusing on registration, scheduling, payments, and clinical support [1] - The software enhances patient intake processes and improves overall patient experiences [1] Recent Performance - Prior to the Q3 2024 earnings report, Phreesia's stock price increased by 21.0% [1] Analyst Background - Dr. Duru, who has been blogging about financial markets since 2000, has extensive experience through various market cycles, including the dot-com bubble, financial crisis, and the coronavirus pandemic [1] - Dr. Duru's blog "One-Twenty Two" offers unique perspectives on financial markets, covering a range of topics including stocks, options, currencies, and Bitcoin [1] - The blog utilizes both technical and fundamental analysis for trading and investing strategies [1]

Phreesia (PHR) shares ended the last trading session 13.9% higher at $21.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.9% loss over the past four weeks.Phreesia scored a strong price increase, driven by investors’ optimism surrounding its impending fiscal 2025 third-quarter results, slated to be released on Dec. 9 after the closing bell. In the fiscal second quarter, Phreesia reached a crucial milestone by ...

Maskot Summary Following my coverage on Phreesia, Inc. (NYSE:PHR) in Jun'24, in which I recommended a buy rating due to my expectation that the business has no issues growing revenue at 20% given that client growth is still strong, this post is to provide an update on my thoughts on the business and stock. I remain buy-rated for PHR as the growth outlook remains solid. New logo adds remain on track to hit FY25 targets, and the increase in transaction size in the current pipeline lends credence to PHR's next ...

Core Insights - Phreesia reported revenue of $102.12 million for the quarter ended July 2024, a year-over-year increase of 19% and a surprise of +0.35% over the Zacks Consensus Estimate of $101.76 million [1] - The company posted an EPS of -$0.31, improving from -$0.68 a year ago, with an EPS surprise of +16.22% compared to the consensus estimate of -$0.37 [1] Revenue Metrics - Average healthcare services clients reached 4,169, slightly above the average estimate of 4,159 based on three analysts [3] - Patient payment volume was reported at $1.09 billion, below the average estimate of $1.13 billion from three analysts [4] - Average revenue per healthcare services client was $17.73 million, compared to the two-analyst average estimate of $18.20 million [5] Segment Revenue Performance - Subscription and related services revenue was $48.61 million, exceeding the average estimate of $47.93 million based on six analysts, representing a year-over-year change of +23.7% [6] - Network solutions revenue was $28.20 million, slightly above the six-analyst average estimate of $28.06 million, with a year-over-year change of +23.2% [7] - Payment processing fees revenue was $25.30 million, below the average estimate of $25.76 million from six analysts, reflecting a year-over-year change of +7.1% [8] Stock Performance - Phreesia shares have returned +4.5% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [8] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [8]

Company Overview - Phreesia is a leading provider of comprehensive solutions that transform the healthcare experience by activating patients in their care[4] - The company empowers healthcare organizations to maximize efficiency, drive growth, and deliver great care with tools that transcend patient intake[4] - Phreesia serves more than 4,100 AHSCs (Average Healthcare Services Clients)[4,10] - The company facilitated over 150 million patient visits in Fiscal Year 2024[4] Financial Performance - Total revenue for the latest twelve months was $390 million[4] - The company experienced 22% total revenue growth in the latest 12 months[4] - Q2 Fiscal Year 2025 total revenue reached $102.1 million, a 19% year-over-year increase[21] - Adjusted EBITDA for Q2 Fiscal Year 2025 was $6.5 million[13,21] - The company processed over $4 billion in patient payments in the latest twelve months[4] Market Opportunity - Phreesia operates in a total addressable market (TAM) of approximately $10 billion[16] - The company estimates $95 billion addressable out-of-pocket spend in the United States[15] Future Outlook - The company projects FY2025 total revenue to be between $416 million and $426 million, representing a 17%-20% year-over-year growth[26] - Phreesia anticipates approximately 4,200 AHSCs by the end of FY2025[26] - The company expects approximately 4,500 AHSCs in FY2026[26]